Eli Lilly's stock growth is being closely watched, with some outlets focusing on the surge in sales of certain medications. The company has reported significant revenue, with one outlet noting a 56% year-over-year increase in GLP-1 sales. However, some reports also suggest that there may be underlying issues or catches to consider when evaluating the stock's performance.